CHARLESTON, S.C. (WCIV) — MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.
Sophie Paczesny, M.D., Ph.D., the principal investigator for this new research, and the co-leader of the Cancer Immunology Program at Hollings Cancer Center, says her main focus is acute myeloid leukemia (AML) and her goal is to find a treatment for it.
“I’ve seen, unfortunately some of my patient dying of leukemia. This is the motivation,” she said. “So, we have now this marker on both the leukemic cell, that’s the seed, and also in the tumor microenvironment, that’s the soil. So, both of them make the tumor go faster. So, our goal, as a translation doc, we want to stop this loop,” she explained…